With growing interest in GLP-1 products such as semaglutide (e.g. Ozempic, Rybelsus, Wegovy) and tirzepatide (e.g. Mounjaro, Zepbound) for weight loss, some people may turn to unauthorized or counterfeit products, which could pose serious health risks because they have not been assessed by Health Canada for safety, effectiveness, or quality. Health Canada has identified various retailers in Canada selling unauthorized GLP-1 products, both in stores and online. Some websites and social media advertisements misuse official Health Canada logos and display fake endorsements to mislead consumers. Health Canada never endorses a health product and does not allow its logo to be used in the advertising or packaging of health products. Risk of using unauthorized or counterfeit products : Unauthorized or counterfeit drugs carry many risks, including: containing too much, too little, or none of the active ingredient containing unlisted, dangerous or unknown ingredients containing contaminants, such as solvents, heavy metals, particles (fibers, glass, plastic), or microbials (bacteria, fungi, endotoxins) being poorly or incorrectly labelled being improperly manufactured or stored Unauthorized or counterfeit injectable products carry even more risks, such as infections due to lack of sterility, allergic reactions, and other serious negative outcomes due to contamination, improper handling, or unsafe administration. Prescription drugs are used to treat specific medical conditions and can cause serious side effects and should only be taken under the guidance and supervision of a healthcare professional. Without proper oversight, there is a risk of harmful drug interactions or adverse effects that a healthcare professional can help to prevent or to manage appropriately. In Canada, only licensed pharmacies can legally sell prescription drugs.
RecallTracker